Subscribe to receive email updates as new information becomes available.

In the face of genetically engineered therapies for many cancers and the incredibly rapid development of effective vaccines for COVID-19, it’s easy to lose sight of the breadth and depth of unsolved puzzles in medical science. Many of these remaining mysteries may be at least partially resolved as we overcome the mind/body dichotomy. A fascinating example of this issue has emerged with recent evidence of the excessive prevalence of Type 1 diabetes (T1D) in transgender children and adults. 

The earliest report of this association came in 2017 from a retrospective study in Belgium that revealed a 2.3-fold higher prevalence of T1D among 1,081 transgender adults, compared to the general population. In 2019, another retrospective study out of the University of Wisconsin looked at 749,284 patients between 10 and 21 years old over a 10-year period.  The prevalence of T1D proved to be 9.5 times greater in the gender dysphoric children than in the remainder of the population. Most recently, a group out of Boston Children’s Hospital reported a prevalence for T1D in their 1,014 transgender youth that is 5.11 times the general population. An additional interesting finding of the latter two studies was that children with gender dysphoria were diagnosed with T1D at a much younger age than the national average. The age of diagnosis in Boston and Wisconsin were 8.5 and 9.9 respectively, compared to the national average of 14.5.

Notably, the dual diagnosis patients across these studies varied. In Belgium, eight of the 10 were transgender women. In Boston, nine of 11 were transgender males, and in Wisconsin there were three transgender males, three transgender females, one identifying as gender fluid, and one as gender neutral. Taking the three studies in aggregate, the correlation of T1D with gender dysphoria appears to exist equally for all transgender people.  

The authors of these studies propose two potential explanations for this surprising correlation.  One is the possibility that people going to endocrinology clinics for T1D may be more likely to identify as gender dysphoric as many transgender and diabetes clinics are co-located. These transgender “friendly” locations may drive increased rates of transgender identification, resulting in the appearance of a correlation with T1D. To the extent there is truth in this hypothesis, it speaks to the importance of providers offering safe, non-judgmental clinical settings where labels are destigmatized, and patients are able to share this critically important information about themselves. 

The second explanation for this finding is that the stress of gender dysphoria acts as a trigger for those with a genetic predisposition to T1D. One argument in favor of the stress as trigger theory, is that patients with T1D who underwent hormonal therapy (either suppression or augmentation) experienced improvement in their HbA1C following the initiation of treatment.  

Though much more work needs to be done to clearly identify the causal relationship between gender dysphoria and Type 1 diabetes, these studies challenge us to overcome our longstanding paradigm that views mind and body separately. Even the idea that the two interact with each other rather than exist as differing manifestations of one whole self should be called into question. To fully understand this and other medical mysteries before us, we may very well need to develop an entirely new vocabulary.   

Subscribe to the NextGen® Advisor blog to keep updated with the latest news and issues impacting the healthcare community.

Meet NextGen Ambient Assist, your new AI ally that generates a structured SOAP note in seconds from listening to the natural patient/provider conversation.

Read Now
Dr Lustick

Dr. Martin Lustick

Senior Vice President, NextGen Advisors

Dr. Martin Lustick is a principal and senior vice president with NextGen Healthcare focused on supporting provider organizations in their successful transition from volume to value-based care.

Dr. Lustick earned a BA in History from Cornell and an MD from Columbia. After completing his pediatric residency at Children’s Hospital National Medical Center in Washington, DC, he was in clinical practice for 17 years with Kaiser Permanente of the Mid-Atlantic States. While there, Dr. Lustick held various management and leadership roles, including chief operating officer for the 800-physician medical group. He oversaw development of their hospitalist program, population health capability, and open access delivery model.

Dr. Lustick then served as chief medical officer for ThompsonHealth—a small health system in Canandaigua, NY—where he provided clinical oversight for hospital, SNF, nursing home, IT, and out-patient physician practices.

In 2005, Dr. Lustick assumed the role of SVP & CMO for Excellus BCBS which covers 1.6 million lives comprised of Medicare, Commercial, and Medicaid. In his 13+ year tenure there he led a variety of strategic initiatives, including a patient-centered medical home program which served as the foundation for the plan’s value-based payment strategy. He also led the implementation of an automated authorization program for care management services, development of a clinical quality improvement strategy, and creation of innovative programs in management of low back pain, screening and prevention, opioid addiction, and chronic disease management.

Dr. Lustick has also been very active in the community, serving on boards and committees confronting issues such as: healthcare capacity planning, Health Information Exchange, mental health, substance use disorders, social determinants of health, and childhood obesity.